|
|
 Previous Article | Table of Contents | Next Article 
Allogeneic marrow transplantation for refractory anemia: a comparison of
two preparative regimens and analysis of prognostic factors
JE Anderson, FR Appelbaum, G Schoch, T Gooley, C Anasetti, WI Bensinger, E Bryant, CD Buckner, TR Chauncey, RA Clift, K Doney, M Flowers, JA Hansen, PJ Martin, DC Matthews, JE Sanders, H Shulman, KM Sullivan, RP Witherspoon and R Storb
Clinical Research Division, Fred Hutchinson Cancer Research Center,
Seattle, WA 98104, USA.
From 1990 to 1993 we performed a prospective study of busulfan (16 mg/kg)
and cyclophosphamide (120 mg/kg) in 30 patients with refractory anemia (RA)
undergoing related (n = 17) or unrelated (n = 13) donor marrow
transplantation. Nineteen patients survive disease free (63% 3- year
actuarial disease-free survival [DFS]) and no patient relapsed. These
results were compared to those of 38 historical controls with RA treated
with cyclophosphamide and total body irradiation, of whom 22 are
disease-free survivors and 1 relapsed. After correcting for significant
variables between the two treatment groups, we found no statistically
significant difference in outcome based on preparative regimen. Combining
data from these 68 patients plus 2 additional patients with RA treated
before 1993 with busulfan and cyclophosphamide, we identified four
variables independently associated with improved survival: younger age,
shorter disease duration, lower neutrophil count pretransplant, and lower
hematocrit pretransplant. We also found that 15 patients 40 to 55 years of
age had a 46% 3-year actuarial DFS and 26 patients receiving unrelated or
mismatched related donor marrow had a 50% 3-year actuarial DFS. We conclude
that there does not appear to be any significant difference in outcome
based on preparative regimen in this patient population. In addition,
allogeneic bone marrow transplantation may be a reasonable approach to
therapy of RA early after diagnosis. However, whether early intervention
with transplantation prolongs survival over that expected without
transplantation cannot be ascertained with certainty from available data.
Volume 87,
Issue 1,
pp. 51-58,
01/01/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. M. Stone
How I treat patients with myelodysplastic syndromes
Blood,
June 18, 2009;
113(25):
6296 - 6303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb
Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation
J. Clin. Oncol.,
September 20, 2007;
25(27):
4246 - 4254.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Cutler, S. J. Lee, P. Greenberg, H. J. Deeg, W. S. Perez, C. Anasetti, B. J. Bolwell, M. S. Cairo, R. P. Gale, J. P. Klein, et al.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
Blood,
July 15, 2004;
104(2):
579 - 585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. List, J. Vardiman, J.-P. J. Issa, and T. M. DeWitte
Myelodysplastic Syndromes
Hematology,
January 1, 2004;
2004(1):
297 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kardos, I. Baumann, S. J. Passmore, F. Locatelli, H. Hasle, K. R. Schultz, J. Stary, A. Schmitt-Graeff, A. Fischer, J. Harbott, et al.
Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7
Blood,
September 15, 2003;
102(6):
1997 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Benesch and H. J. Deeg
Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders
Mayo Clin. Proc.,
August 1, 2003;
78(8):
981 - 990.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Bornhauser, B. Storer, J. T. Slattery, F. R. Appelbaum, H. J. Deeg, J. Hansen, P. J. Martin, G. B. McDonald, W. G. Nichols, J. Radich, et al.
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
Blood,
August 1, 2003;
102(3):
820 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sierra, W. S. Perez, C. Rozman, E. Carreras, J. P. Klein, J. D. Rizzo, S. M. Davies, H. M. Lazarus, C. N. Bredeson, D. I. Marks, et al.
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia
Blood,
August 28, 2002;
100(6):
1997 - 2004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Deeg, B. Storer, J. T. Slattery, C. Anasetti, K. C. Doney, J. A. Hansen, H.-P. Kiem, P. J. Martin, E. Petersdorf, J. P. Radich, et al.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
Blood,
July 30, 2002;
100(4):
1201 - 1207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Guardiola, V. Runde, A. Bacigalupo, T. Ruutu, F. Locatelli, M. A. Boogaerts, A. Pagliuca, J. J. Cornelissen, H. C. Schouten, E. Carreras, et al.
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
Blood,
May 29, 2002;
99(12):
4370 - 4378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, P. Meyer, D. Dutt, F. Zorat, L. Lisak, F. Nascimben, M. du Randt, C. Kaspar, C. Goldberg, J. Loew, et al.
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
Blood,
August 15, 2001;
98(4):
958 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Witherspoon, H. J. Deeg, B. Storer, C. Anasetti, R. Storb, and F. R. Appelbaum
Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia
J. Clin. Oncol.,
April 15, 2001;
19(8):
2134 - 2141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, H. Qawi, L. Lisak, T. Andric, S. Dar, C. Andrews, P. Venugopal, S. Gezer, S. Gregory, J. Loew, et al.
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
Blood,
March 1, 2000;
95(5):
1580 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Deeg, H. M. Shulman, J. E. Anderson, E. M. Bryant, T. A. Gooley, J. T. Slattery, C. Anasetti, A. Fefer, R. Storb, and F. R. Appelbaum
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
Blood,
February 15, 2000;
95(4):
1188 - 1194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Nevill, H. C. Fung, J. D. Shepherd, D. E. Horsman, S. H. Nantel, H.-G. Klingemann, D. L. Forrest, C. L. Toze, H. J. Sutherland, D. E. Hogge, et al.
Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation
Blood,
September 15, 1998;
92(6):
1910 - 1917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Kouides and J. M. Bennett
Understanding the Myelodysplastic Syndromes
Oncologist,
December 1, 1997;
2(6):
389 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Anderson, T. A. Gooley, G. Schoch, C. Anasetti, W. I. Bensinger, R. A. Clift, J. A. Hansen, J. E. Sanders, R. Storb, and F. R. Appelbaum
Stem Cell Transplantation for Secondary Acute Myeloid Leukemia: Evaluation of Transplantation as Initial Therapy or Following Induction Chemotherapy
Blood,
April 1, 1997;
89(7):
2578 - 2585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
